Literature DB >> 34957154

Is the Infection of the SARS-CoV-2 Delta Variant Associated With the Outcomes of COVID-19 Patients?

Mohamad Saifudin Hakim1, Hendra Wibawa2, Vivi Setiawaty3, Ika Trisnawati4, Endah Supriyati5, Riat El Khair6, Kristy Iskandar7, Nungki Anggorowati8, Edwin Widyanto Daniwijaya1, Dwi Aris Agung Nugrahaningsih9, Yunika Puspadewi6, Dyah Ayu Puspitarani10, Irene Tania10, Khanza Adzkia Vujira10, Muhammad Buston Ardlyamustaqim10, Gita Christy Gabriela10, Laudria Stella Eryvinka10, Bunga Citta Nirmala10, Esensi Tarian Geometri10, Abirafdi Amajida Darutama10, Anisa Adityarini Kuswandani10, Sri Handayani Irianingsih2, Siti Khoiriyah11, Ina Lestari11, Nur Rahmi Ananda4, Eggi Arguni7, Titik Nuryastuti1, Tri Wibawa1.   

Abstract

Background: Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) Delta variant (B.1.617.2) has been responsible for the current increase in Coronavirus disease 2019 (COVID-19) infectivity rate worldwide. We compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia.
Methods: In this cross-sectional study, we ascertained 161 patients, 69 with the Delta variant and 92 with the non-Delta variant. The Illumina MiSeq next-generation sequencer was used to perform the whole-genome sequences of SARS-CoV-2.
Results: The mean age of patients with the Delta variant and the non-Delta variant was 27.3 ± 20.0 and 43.0 ± 20.9 (p = 3 × 10-6). The patients with Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females (p = 0.001). The Ct value of the Delta variant (18.4 ± 2.9) was significantly lower than that of the non-Delta variant (19.5 ± 3.8) (p = 0.043). There was no significant difference in the hospitalization and mortality of patients with Delta and non-Delta variants (p = 0.80 and 0.29, respectively). None of the prognostic factors were associated with the hospitalization, except diabetes with an OR of 3.6 (95% CI = 1.02-12.5; p = 0.036). Moreover, the patients with the following factors have been associated with higher mortality rate than the patients without the factors: age ≥65 years, obesity, diabetes, hypertension, and cardiovascular disease with the OR of 11 (95% CI = 3.4-36; p = 8 × 10-5), 27 (95% CI = 6.1-118; p = 1 × 10-5), 15.6 (95% CI = 5.3-46; p = 6 × 10-7), 12 (95% CI = 4-35.3; p = 1.2 × 10-5), and 6.8 (95% CI = 2.1-22.1; p = 0.003), respectively. Multivariate analysis showed that age ≥65 years, obesity, diabetes, and hypertension were the strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI = 0.58-21.9; p = 0.028), 16.6 (95% CI = 2.5-107.1; p = 0.003), 5.5 (95% CI = 1.3-23.7; p = 0.021), and 5.8 (95% CI = 1.02-32.8; p = 0.047), respectively. Conclusions: We show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms that older age and comorbidity increase the mortality rate of patients with COVID-19.
Copyright © 2021 Gunadi, Hakim, Wibawa, Marcellus, Setiawaty, Slamet, Trisnawati, Supriyati, El Khair, Iskandar, Afiahayati, Siswanto, Irene, Anggorowati, Daniwijaya, Nugrahaningsih, Puspadewi, Puspitarani, Tania, Vujira, Ardlyamustaqim, Gabriela, Eryvinka, Nirmala, Geometri, Darutama, Kuswandani, Lestari, Irianingsih, Khoiriyah, Lestari, Ananda, Arguni, Nuryastuti and Wibawa.

Entities:  

Keywords:  Ct value; SARS-CoV-2; comorbidity; delta variant; hospitalization; mortality; viral load; whole genome sequencing

Year:  2021        PMID: 34957154      PMCID: PMC8695874          DOI: 10.3389/fmed.2021.780611

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  33 in total

Review 1.  COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations.

Authors:  Bin Zhou; Shinsuke Kojima; Atsuhiko Kawamoto; Masanori Fukushima
Journal:  J Med Virol       Date:  2021-01-11       Impact factor: 2.327

2.  A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences.

Authors:  M Kimura
Journal:  J Mol Evol       Date:  1980-12       Impact factor: 2.395

3.  Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta).

Authors:  Sean Wei Xiang Ong; Calvin J Chiew; Li Wei Ang; Tze Minn Mak; Lin Cui; Matthias Paul H S Toh; Yi Ding Lim; Pei Hua Lee; Tau Hong Lee; Po Ying Chia; Sebastian Maurer-Stroh; Raymond T P Lin; Yee Sin Leo; Vernon J Lee; David Chien Lye; Barnaby Edward Young
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

4.  Effective public health measures to mitigate the spread of COVID-19: a systematic review.

Authors:  Imen Ayouni; Jihen Maatoug; Wafa Dhouib; Nawel Zammit; Sihem Ben Fredj; Rim Ghammam; Hassen Ghannem
Journal:  BMC Public Health       Date:  2021-05-29       Impact factor: 3.295

5.  DAMBE7: New and Improved Tools for Data Analysis in Molecular Biology and Evolution.

Authors:  Xuhua Xia
Journal:  Mol Biol Evol       Date:  2018-06-01       Impact factor: 16.240

6.  Full-length genome characterization and phylogenetic analysis of SARS-CoV-2 virus strains from Yogyakarta and Central Java, Indonesia.

Authors:  Hendra Wibawa; Mohamad Saifudin Hakim; Edwin Widyanto Daniwijaya; Ludhang Pradipta Rizki; Endah Supriyati; Dwi Aris Agung Nugrahaningsih; Kristy Iskandar; Nungki Anggorowati; Alvin Santoso Kalim; Dyah Ayu Puspitarani; Kemala Athollah; Eggi Arguni; Titik Nuryastuti; Tri Wibawa
Journal:  PeerJ       Date:  2020-12-21       Impact factor: 2.984

Review 7.  SARS-CoV-2, Covid-19, and the debunking of conspiracy theories.

Authors:  Mohamad S Hakim
Journal:  Rev Med Virol       Date:  2021-02-14       Impact factor: 11.043

8.  Lifting of COVID-19 restrictions in the UK and the Delta variant.

Authors:  Talha Khan Burki
Journal:  Lancet Respir Med       Date:  2021-07-12       Impact factor: 30.700

Review 9.  COVID-19 and comorbidities: Deleterious impact on infected patients.

Authors:  Hasan Ejaz; Abdullah Alsrhani; Aizza Zafar; Humera Javed; Kashaf Junaid; Abualgasim E Abdalla; Khalid O A Abosalif; Zeeshan Ahmed; Sonia Younas
Journal:  J Infect Public Health       Date:  2020-08-04       Impact factor: 3.718

View more
  6 in total

1.  Tracking the molecular evolution and transmission patterns of SARS-CoV-2 lineage B.1.466.2 in Indonesia based on genomic surveillance data.

Authors:  Mingjian Zhu; Qianli Zeng; Bryanna Infinita Laviashna Saputro; Sien Ping Chew; Ian Chew; Holie Frendy; Joanna Weihui Tan; Lanjuan Li
Journal:  Virol J       Date:  2022-06-16       Impact factor: 5.913

2.  Evolutionary dynamics of SARS-CoV-2 circulating in Yogyakarta and Central Java, Indonesia: sequence analysis covering furin cleavage site (FCS) region of the spike protein.

Authors:  Nastiti Wijayanti; Faris Muhammad Gazali; Endah Supriyati; Mohamad Saifudin Hakim; Eggi Arguni; Marselinus Edwin Widyanto Daniwijaya; Titik Nuryastuti; Matin Nuhamunada; Rahma Nabilla; Sofia Mubarika Haryana; Tri Wibawa
Journal:  Int Microbiol       Date:  2022-02-14       Impact factor: 3.097

3.  Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis.

Authors:  Christine J Lee; Wongi Woo; Ah Young Kim; Dong Keon Yon; Seung Won Lee; Ai Koyanagi; Min Seo Kim; Kalthoum Tizaoui; Elena Dragioti; Joaquim Radua; Sungsoo Lee; Lee Smith; Jae Il Shin
Journal:  J Med Virol       Date:  2022-06-01       Impact factor: 20.693

4.  Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity.

Authors:  Koji Tsuchiya; Norio Yamamoto; Yoshie Hosaka; Mitsuru Wakita; Makoto Hiki; Yasushi Matsushita; Hirotake Mori; Satoshi Hori; Shigeki Misawa; Takashi Miida; Shuko Nojiri; Kazuhisa Takahashi; Toshio Naito; Yoko Tabe
Journal:  Front Microbiol       Date:  2022-07-27       Impact factor: 6.064

5.  Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants.

Authors:  Oleksandr Oliynyk; Wojciech Barg; Yanina Oliynyk; Serhij Dubrov; Vitaliy Gurianov; Marta Rorat
Journal:  J Pers Med       Date:  2022-07-04

Review 6.  Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.

Authors:  Miguel A Ortega; Cielo García-Montero; Oscar Fraile-Martinez; Paolo Colet; Ardak Baizhaxynova; Kymbat Mukhtarova; Melchor Alvarez-Mon; Kaznagul Kanatova; Angel Asúnsolo; Antonio Sarría-Santamera
Journal:  J Pers Med       Date:  2022-06-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.